Search Results

You are looking at 1 - 10 of 11 items for :

  • "trimetazidine" x
  • All content x
Clear All

WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003; 14: 171–179. 3

Open access

, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PloS ONE 2012; 7: e36284. 11 Dézsi CA. Trimetazidine in practice: review of

Restricted access
Summary A validated reversed-phase thin-layer chromatography (RP-TLC)–densitometry method was developed and optimized for the determination of trimetazidine dihydrochloride (TMZ) and its potential impurities listed in the British Pharmacopoeia, namely, piperazinecarboxaldehyde (Y-145), trimethoxybenzyl alcohol (Y-235), and trimethoxybenzaldehyde (Y-234). Chromatographic separation was performed on aluminum plates pre-coated with silica gel 60 RP-18F using a mixture of acetonitrile–methanol–0.1% aqueous ortho-phosphoric acid pH 6.2 (4.5:4.5:1, V/V) as the developing system. Different factors affecting resolution were studied and optimized. Successful resolution was observed with significant difference in the RF values of 0.21 ± 0.02, 0.35 ± 0.02, 0.5 ± 0.02, and 0.85± 0.02 for TMZ and its impurities, respectively. Densitometric measurement was done at 215 nm over the range of 0.05–10, 0.05–1.1, 0.05–1.2, and 0.04–1.0 µg per spot with lower limits of detection (LOD) and quantification (LOQ) of 20 and 50 ng per spot for TMZ, Y-145, and Y-235, respectively, and 15 and 40 ng per spot for Y-234 impurity. Good accuracy was obtained with mean percentage recoveries of 99.55 ± 1.06, 100.50 ± 1.16, 100.07 ± 1.24, and 99.41 ± 1.11 for TMZ and its impurities, respectively. The developed method was used to investigate the impurity profile of TMZ in drug substance and different products and it was validated as per the International Conference on Harmonisation (ICH) guidelines.
Restricted access

Hungary: Cross-sectional study on nationally representative sample of people aged 20–69 years. Croat. Med. J., 2010, 51 (2), 151–156. 3 Dézsi, C. A.: Trimetazidine

Open access

trimetazidine in cochleovestibular disorders of ischemic origin. A crossover control versus placebo trial Annales d'Oto-Larygologe et de Chirurge Cervico-Faciale 1 107Suppl 81 – 87 . [42]. R. Belardinelli M. Solenghi L. Volpe 2007

Restricted access

22 797 801 Coyas, A.: The efficacy of trimetazidine in cochleovostibular disorders of ischemic origin. A crossover control versus

Restricted access

22 797 801 Coyas, A.: The efficacy of trimetazidine in cochleovestibular disorders of ischemic origin. A crossover control versus

Restricted access

.: Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats. Int. J. Cardiol., 2013, 167 (1), 126

Restricted access

MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH: The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 93, e26

Restricted access

1936 Marzilli, M., Klein, W.: Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double blind, controlled trials. Coronary Artery Dis

Restricted access